EUVIMEDEUVIMED entdecken
Crossref

BDNF and proBDNF serum levels during antidepressant treatment in adolescent girls with a first-lifetime episode of depression: A prospective case-controlled study

Weronika Zwolińska, Karolina Bilska, Maria Skibińska, Natalia Pytlińska, Agnieszka Słopień, Monika Dmitrzak-Węglarz

Journal of Affective Disorders · 2025

DOI: 10.1016/j.jad.2025.02.038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Weronika Zwolińska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Poznan University of Medical Sciences, Department of Child and Adolescent Psychiatry, Karol Jonscher Clinical Hospital, Szpitalna St. 27/33, 60-572 P…. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Antidepressive Agents, Protein Precursors, Depressive Disorder. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: As one of the most promising biomarkers in depression course and treatment, the brain-derived neurotrophic factor (BDNF) has been identified as a possible predictor of antidepressant treatment outcomes in the adult population. However, studies on this subject in the developmental population are lacking. We aimed to verify the changes in serum BDNF, proBDNF, and BDNF/proBDNF ratio levels during antidepressant treatment in adolescents diagnosed with depressive episodes. We also investigated these parameters as predictors of antidepressant treatment outcomes. MATERIAL AND METHODS: Thirty female inpatients, aged 11-17, diagnosed with a first-lifetime depressive episode were assessed at two time-points: before (t0) and after (t1) the period of antidepressant treatment and compared with thirty age-matched healthy girls. The assessment at t0 and t1 involved BDNF and proBDNF serum levels (analyzed with the ELISA method) and standardized depressive symptoms scales. RESULTS: BDNF serum levels decreased significantly with the antidepressant treatment in the studied group (p = 0.0224). This effect was still present in the subgroup of responders (p = 0.0179) but not among non-responders (p = 0.2184). Responders had a significantly higher initial BDNF/proBDNF ratio than non-responders. The BDNF/proBDNF ratio at t0 could predict the remission status at t1 with a sensitivity of 66.67 % and a specificity of 81.25 % (p = 0.0327). CONCLUSIONS: BDNF serum levels tend to decrease with successful antidepressant treatment in adolescent girls treated for the first episode of depression. Pretreatment BDNF/proBDNF ratio should be considered a possible biomarker predictive of antidepressant treatment response in adolescent girls.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain-Derived Neurotrophic FactorAntidepressive AgentsProtein PrecursorsDepressive DisorderMajor Depressive DisorderHumansFemaleAdolescentProspective StudiesCase-Control StudiesChildBiomarkersTreatment Outcome

Stichwörter der Autor:innen

AdolescenceBDNFBiomarkersDepressionPro-BDNF

Substanzen

Brain-Derived Neurotrophic FactorAntidepressive AgentsBiomarkersProtein PrecursorsBDNF protein, humanbrain-derived neurotrophic factor precursor

Autor:innen und Institutionen

  • Poznan University of Medical Sciences, Department of Child and Adolescent Psychiatry, Karol Jonscher Clinical Hospital, Szpitalna St. 27/33, 60-572 Poznan, Poland; Poznan University of Medical Sciences, Doctoral School,…
  • Poznan University of Medical Sciences, Department of Psychiatric Genetics, Medical Biology Center, Rokietnicka St. 8, 60-806 Poznan, Poland. Electronic address: kbilska@ump.edu.pl.
  • Poznan University of Medical Sciences, Department of Psychiatric Genetics, Medical Biology Center, Rokietnicka St. 8, 60-806 Poznan, Poland. Electronic address: mariaski@ump.edu.pl.
  • Poznan University of Medical Sciences, Department of Child and Adolescent Psychiatry, Karol Jonscher Clinical Hospital, Szpitalna St. 27/33, 60-572 Poznan, Poland. Electronic address: nataliapytlinska@ump.edu.pl.
  • Poznan University of Medical Sciences, Department of Child and Adolescent Psychiatry, Karol Jonscher Clinical Hospital, Szpitalna St. 27/33, 60-572 Poznan, Poland. Electronic address: agaslopien@ump.edu.pl.
  • Poznan University of Medical Sciences, Department of Psychiatric Genetics, Medical Biology Center, Rokietnicka St. 8, 60-806 Poznan, Poland. Electronic address: mweglarz@ump.edu.pl.

Förderung

  • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Zitieren

APA

Zwolińska, W., Bilska, K., Skibińska, M., Pytlińska, N., Słopień, A., & Dmitrzak-Węglarz, M. (2025). BDNF and proBDNF serum levels during antidepressant treatment in adolescent girls with a first-lifetime episode of depression: A prospective case-controlled study. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.02.038

Vancouver

Zwolińska W, Bilska K, Skibińska M, Pytlińska N, Słopień A, Dmitrzak-Węglarz M. BDNF and proBDNF serum levels during antidepressant treatment in adolescent girls with a first-lifetime episode of depression: A prospective case-controlled study. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.02.038

BibTeX
@article{Zwoliska2025,
  author = {Zwolińska, Weronika and Bilska, Karolina and Skibińska, Maria and Pytlińska, Natalia and Słopień, Agnieszka and Dmitrzak-Węglarz, Monika},
  title = {BDNF and proBDNF serum levels during antidepressant treatment in adolescent girls with a first-lifetime episode of depression: A prospective case-controlled study},
  journal = {Journal of Affective Disorders},
  year = {2025},
  doi = {10.1016/j.jad.2025.02.038}
}
Kostenlos starten →